Report ID : 10082368 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Global Xerostomia (Dry Mouth) Therapeutics Market Highlights Over 2022 - 2031
The global xerostomia (dry mouth) therapeutics market generated nearly USD 680 million in year 2021 and is estimated to garner modest revenue by the end of 2031, growing at a CAGR of ~6% over the forecast period, i.e., 2022 – 2031. The growth of the market can primarily be attributed to the high prevalence of the disease and insufficient production of saliva in adults mostly aged 50 and above. The side effects caused by hard pharmaceutical drugs is another factor expected to add in the growth of the market. The data estimate for xerostomia or dry mouth in the adults of age 50 or over accounts for 10% and about 40% in the adults over the age of 65. It is anticipated that the xerostomia therapeutics market is growing majorly as a result of the increase in associated diseases, such as cancer, diabetes, hypertension, and others among the elderly population. As per the report named “The Global Burden of Disease Study 2017” of the World Health Organization (WHO), oral diseases affected 3.5 billion people worldwide.
-Therapeutics-Market.jpg )
CLICK TO DOWNLOAD SAMPLE REPORT
Dry mouth, or xerostomia, is the cause of insufficient production of saliva (spit) which as a result, can lead to tooth decay. Dry mouth is a symptom of a condition and not a condition itself. Mostly, it is the side effect of medications such as antihistamines or decongestants which is used for the treatment of allergies and cold. These medicines are wildly popular among the people of age 50 and over, hence, causing dry mouth prominently in their age group.
The global xerostomia therapeutics market is segmented by type, product, and by distribution channel. Under type, the market is further segmented into artificial saliva and salivary stimulants. Amongst these, the artificial saliva segment is anticipated to hold the largest market share by growing with a steady CAGR over the forecast period. This growth can be attributed to the availability of effective treatment and easy handling of product. Artificial saliva is a liquid or aerosol product that is sprayed into the mouth or used as a gel. This is not only an easy-to-use product but gives equally effective results.
Global Xerostomia Therapeutics Market Regional Synopsis
Regionally, the global xerostomia therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region witnessed noteworthy growth in the year 2021. Alternatively, the market in the Asia Pacific region is estimated to witness significant growth during the forecast period on the back of increasing funding towards the healthcare sector, growing awareness about treatments, and rising events of conditions such as Parkinson's disease, cancer, diabetes mellitus, and HIV which cause problems of dry mouth. In the year 2019, an average of 5.8 million people were infected with HIV in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global xerostomia therapeutics market includes the following segments:
By Type
-
Artificial Saliva/Saliva Substitutes
-
Salivary Stimulants
By Product
-
Drugs
-
Salivary Pens
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Drug Store
-
Online Pharmacies
Growth Drivers and Challenges Impacting the Growth of the Global Xerostomia Therapeutics Market
Growth Drivers
-
Increasing use of prescriptive medication
-
Side effects of radiation therapy and chemotherapy that causes dry mouth
-
Easy availability of medication
-
Increasing incidence of diseases such as HIV, diabetes, and others
Challenges
-
Lack of awareness about the treatment among people
Key Companies Dominating the Global Xerostomia Therapeutics Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global xerostomia therapeutics market that are included in our report are Colgate-Palmolive Company, EUSA Pharma, GlaxoSmithKline plc, Forward Science, OraPharma (Bausch Health Companies Inc.), Parnell Pharmaceuticals, Inc., Eisai Co., Ltd., Sun Pharmaceuticals Industries Ltd., Saliwel Ltd., and Mission Pharmacal Company among others.
Latest Developments in the Global Xerostomia Therapeutics Market:
-
20 December 2021: “Filgotinib”, an oral, JAK1 selective inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn's disease, has been commercialized by Eisai Co., Ltd. in agreement with Gilead Sciences, Inc. in Asia.
-
24 January 2022: Colgate-Palmolive Company to partner with 3Shape to introduce Colgate Illuminator, an innovative personalized tooth whitening tool, across the dental clinics in the U.S.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
